FOLFOX Regimen Dosing and Administration
The standard FOLFOX regimen (mFOLFOX6) consists of oxaliplatin 85 mg/m² IV over 2 hours on day 1, leucovorin 400 mg/m² IV over 2 hours on day 1,5-FU 400 mg/m² IV bolus on day 1, followed by 5-FU 1200 mg/m²/day continuous infusion for 2 days (total 2400 mg/m² over 46-48 hours), repeated every 2 weeks. 1, 2, 1, 3
Standard Dosing Components
mFOLFOX6 (Most Commonly Used)
- Oxaliplatin: 85 mg/m² IV infusion over 2 hours, day 1
- Leucovorin: 400 mg/m² IV infusion over 2 hours, day 1 (or levoleucovorin 200 mg/m²)
- 5-FU bolus: 400 mg/m² IV push on day 1
- 5-FU infusion: 1200 mg/m²/day continuous IV infusion × 2 days (total 2400 mg/m² over 46-48 hours)
- Cycle frequency: Every 2 weeks 1, 2, 1, 3
Alternative FOLFOX4 Regimen
- Oxaliplatin: 85 mg/m² IV over 2 hours, day 1
- Leucovorin: 200 mg/m² IV over 2 hours, days 1 and 2
- 5-FU: 400 mg/m² IV bolus followed by 600 mg/m² over 22 hours continuous infusion on days 1 and 2
- Cycle frequency: Every 2 weeks 2, 3
Administration Details
Infusion Rates and Timing
Oxaliplatin can be safely infused at 1 mg/m²/min (e.g., 85 mg/m² over 85 minutes instead of the traditional 120 minutes) without increasing hypersensitivity reaction rates 4. The traditional 2-hour infusion remains standard in guidelines but can be shortened for efficiency.
Critical Ordering Safety
Always order 5-FU continuous infusions in 24-hour units (1200 mg/m²/day for 2 days) rather than total dose over 46-48 hours to minimize medication errors 2.
Treatment Duration
Adjuvant Setting
- Standard duration: 12 cycles (6 months) 1, 3
- Shortened duration: 8 cycles (3 months) of CAPEOX may be considered for high-risk stage II and low-risk stage III (T1-3N1) colon cancer based on IDEA study results 1, 5
- Initiate within 3 weeks post-surgery, no later than 2 months 1
Metastatic/Advanced Setting
- Continue until disease progression, unacceptable toxicity, or patient refusal 3
- Consider oxaliplatin discontinuation after 3 months (6 cycles) to prevent cumulative neurotoxicity while continuing 5-FU/LV 6
Key Management Considerations
Neurotoxicity Management
Discontinue oxaliplatin from FOLFOX after 3 months or sooner if unacceptable neurotoxicity develops, while maintaining 5-FU/LV for the full 6 months 6. Do not restart oxaliplatin until near-complete resolution of neurotoxicity occurs.
Dose Modifications
- North American patients may require lower capecitabine doses (850 mg/m² vs 1000 mg/m² twice daily) in CAPEOX due to increased fluoropyrimidine toxicity compared to European patients 2
- Leucovorin 400 mg/m² is equivalent to levoleucovorin 200 mg/m² 2
Common Pitfalls
- Do not use bolus 5-FU regimens with oxaliplatin - infusional 5-FU is required for safety and efficacy 2
- Avoid calcium/magnesium infusions for neuropathy prevention - they are ineffective 6
- Patients ≥70 years may not benefit from oxaliplatin addition to 5-FU/LV 1
Special Populations
In hemodialysis patients, oxaliplatin can be administered at standard doses if dialysis is performed 1 hour after infusion completion 7. Dose reduction is not necessarily required with this approach.